Routine vaccination against MenB: considerations for implementation.

Area of Science:

• Vaccinology
• Infectious Diseases
• Public Health

Background:

• Serogroup B meningococci (MenB) are a significant cause of invasive meningococcal disease (IMD), particularly in infants, despite available vaccines for other serogroups.
• The 4CMenB vaccine (Bexsero®), comprising recombinant proteins and outer membrane vesicles, is now licensed for individuals aged 2 months and older in Europe and Australia.

Purpose of the Study:

• To discuss key considerations for the successful implementation of a broad-coverage MenB vaccine into national immunization programs.
• To highlight factors influencing the selection of an appropriate immunization strategy for MenB vaccines.

Main Methods:

• Review of epidemiological data relevant to MenB disease burden.
• Analysis of vaccine characteristics, including coverage, immunogenicity, and cost-effectiveness.
• Consideration of post-implementation surveillance strategies, including impact on strain variation, carriage, and adverse events.

Main Results:

• Successful implementation necessitates a comprehensive approach integrating epidemiological insights with vaccine performance data.
• Post-implementation surveillance is crucial for monitoring vaccine effectiveness, potential shifts in meningococcal strains, and safety.

Conclusions:

• A successful MenB vaccine rollout requires strategic planning that encompasses epidemiology, vaccine properties, cost, and robust surveillance.
• Ongoing monitoring of vaccine effectiveness, strain dynamics, and safety is essential for long-term public health impact.